Skip to main content

Articles

Page 32 of 38

  1. The advent of tyrosine kinase inhibitors has produced 5-year survival of 90 + % for chronic myelocytic leukemia (CML) patients in clinical trials. However, population level survival has been lower, especially ...

    Authors: Dianne Pulte, Benjamin Barnes, Lina Jansen, Nora Eisemann, Katharina Emrich, Adam Gondos, Stefan Hentschel, Bernd Holleczek, Klaus Kraywinkel and Hermann Brenner
    Citation: Journal of Hematology & Oncology 2013 6:70
    Content type: Research Published on:

  2. Peripheral T/NK-cell lymphomas (PTCL) are rare malignancies with a poor prognosis. Due to the lack of randomised studies, standard therapy has not been established. First-line treatment with anthracycline-base...

    Authors: Peter Reimer and Shanta Chawla
    Citation: Journal of Hematology & Oncology 2013 6:69
    Content type: Case report Published on:

  3. We have characterized the molecular changes underlying the transformation of a JAK2V617F+-myelofibrosis with trisomy 8, into a JAK2V617F-negative leukemia. Leukemic clone did not carry JAK2V617F mutation, but sho...

    Authors: Francisca Ferrer-Marín, Beatriz Bellosillo, Luz Martínez-Avilés, Gloria Soler, Pablo Carbonell, Ginés Luengo-Gil, Eva Caparrós, José M Torregrosa, Carlos Besses and Vicente Vicente
    Citation: Journal of Hematology & Oncology 2013 6:68
    Content type: Letter to the Editor Published on:

  4. Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive malignancy with only a 5% 5-year survival rate. Reliable biomarkers for early detection are still lacking. The goals of this study were (a) to ide...

    Authors: Michela Capello, Paola Cappello, Federica Caterina Linty, Roberto Chiarle, Isabella Sperduti, Anna Novarino, Paola Salacone, Giorgia Mandili, Alessio Naccarati, Carlotta Sacerdote, Stefania Beghelli, Samantha Bersani, Stefano Barbi, Claudio Bassi, Aldo Scarpa, Paola Nisticò…
    Citation: Journal of Hematology & Oncology 2013 6:67
    Content type: Research Published on:

  5. Gastroesophageal cancer (GEC) remains a challenging problem in oncology. Anatomically, GEC is comprised of distal gastric adenocarcinoma (GC), classically associated with Helicobacter Pylori, while proximal esoph...

    Authors: Amikar Sehdev and Daniel VT Catenacci
    Citation: Journal of Hematology & Oncology 2013 6:66
    Content type: Review Published on:

  6. Erythropoietin (EPO) provides an alternative to transfusion for increasing red blood cell mass and treating anemia in cancer patients. However, recent studies have reported increased adverse events and/or redu...

    Authors: Makito Miyake, Steve Goodison, Adrienne Lawton, Ge Zhang, Evan Gomes-Giacoia and Charles J Rosser
    Citation: Journal of Hematology & Oncology 2013 6:65
    Content type: Research Published on:

  7. Despite the success of imatinib and other tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML) remains largely incurable, and a number of CML patients die due to Abl mutation-related drug resistance ...

    Authors: Qi Shen, Sichu Liu, Yu Chen, Lijian Yang, Shaohua Chen, Xiuli Wu, Bo Li, Yuhong Lu, Kanger Zhu and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2013 6:64
    Content type: Research Published on:

  8. The natural history of inhibitors in patients with haemophilia A not undergoing immune tolerance induction (ITI) is largely unknown. A recent randomized controlled trial suggests that the higher the FVIII dose...

    Authors: Giuseppe Tagariello, Alfonso Iorio, Davide Matino, Donata Belvini, Roberta Salviato, Roberto Sartori and Paolo Radossi
    Citation: Journal of Hematology & Oncology 2013 6:63
    Content type: Research Published on:

  9. High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of pa...

    Authors: Rajendra Gharbaran, Andre Goy, Takemi Tanaka, Jongwhan Park, Chris Kim, Nafis Hasan, Swathi Vemulapalli, Sreeja Sarojini, Madalina Tuluc, Kip Nalley, Pritish Bhattacharyya, Andrew Pecora and K Stephen Suh
    Citation: Journal of Hematology & Oncology 2013 6:62
    Content type: Research Published on:

  11. Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it i...

    Authors: Yue Wang, Yiying Wang, Jie Li, Zeng Yuan, Bingbing Yuan, Tingguo Zhang, Janiel M Cragun, Beihua Kong and Wenxin Zheng
    Citation: Journal of Hematology & Oncology 2013 6:60
    Content type: Research Published on:

  12. Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer patients. Recently Bruton’s tyrosine kinase (BTK), a cru...

    Authors: Akintunde Akinleye, Yamei Chen, Nikhil Mukhi, Yongping Song and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:59
    Content type: Review Published on:

  13. Myelodysplastic syndromes (MDS) are hematological malignancies of unclear etiology where oxidative stress may contribute to the pathogenesis. Methylarginines, naturally occurring inhibitors of NO synthase, can...

    Authors: Jana Štikarová, Jiří Suttnar, Kristýna Pimková, Leona Chrastinová-Mášová, Jaroslav Čermák and Jan E Dyr
    Citation: Journal of Hematology & Oncology 2013 6:58
    Content type: Letter to the Editor Published on:

  15. High concentrations of plasmatic IgE have been related to distinct systemic inflammatory conditions that frequently predispose individuals to hypersensitivity reactions. Although effects of IgE have been sugge...

    Authors: Guillermina Yanek Jiménez-Andrade, Alfredo Ibarra-Sánchez, Diana González, Mónica Lamas and Claudia González-Espinosa
    Citation: Journal of Hematology & Oncology 2013 6:56
    Content type: Research Published on:

  16. Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma,...

    Authors: Madhav Desai, Kate J Newberry, Jorge Romaguera, Liang Zhang, Zhishuo Ou and Michael Wang
    Citation: Journal of Hematology & Oncology 2013 6:55
    Content type: Review Published on:

  18. Burkitt leukemia/lymphoma is a major subtype of aggressive B-cell lymphoma. Biological targeted therapies on this disease need to be further investigated and may help to improve the clinical outcome of the pat...

    Authors: Li Hua Dong, Shu Cheng, Zhong Zheng, Li Wang, Yang Shen, Zhi Xiang Shen, Sai Juan Chen and Wei Li Zhao
    Citation: Journal of Hematology & Oncology 2013 6:53
    Content type: Research Published on:

  19. The current study evaluated the differential expression detected in the proteomic profiles of low risk- and high risk- ALL pediatric patients to characterize candidate biomarkers related to diagnosis, prognosi...

    Authors: Maria Braoudaki, George I Lambrou, Konstantinos Vougas, Kalliopi Karamolegou, George T Tsangaris and Fotini Tzortzatou-Stathopoulou
    Citation: Journal of Hematology & Oncology 2013 6:52
    Content type: Research Published on:

  20. To investigate the hypothesis that MRI derived diffusion-weighted imaging (DWI) and perfusion (MRP) parameters are sensitive image biomarkers for monitoring early antiangiogenic effects and predicting progress...

    Authors: Dushyant V Sahani, Tao Jiang, Koichi Hayano, Dan G Duda, Onofrio A Catalano, Marek Ancukiewicz, Rakesh K Jain and Andrew X Zhu
    Citation: Journal of Hematology & Oncology 2013 6:51
    Content type: Research Published on:

  21. Myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized by ineffective hematopoiesis that results in reduced blood counts. Although MDS can transform into leukemia, most of the morbi...

    Authors: Lohith Bachegowda, Oleg Gligich, Ionnis Mantzaris, Carolina Schinke, Dale Wyville, Tatiana Carrillo, Ira Braunschweig, Ulrich Steidl and Amit Verma
    Citation: Journal of Hematology & Oncology 2013 6:50
    Content type: Review Published on:

  22. Multidrug resistance (MDR) is one of the major problems in the treatment of cancer. Overcoming it is therefore expected to improve clinical outcomes for cancer patients. MDR is usually characterized by overexp...

    Authors: Limin Huang, Christelle Perrault, Jennifer Coelho-Martins, Chaoquan Hu, Charlène Dulong, Mariana Varna, Jielin Liu, Jian Jin, Claudine Soria, Lionel Cazin, Anne Janin, Hong Li, Rémi Varin and He Lu
    Citation: Journal of Hematology & Oncology 2013 6:49
    Content type: Research Published on:

  23. Ridaforolimus (AP23573, MK-8669 or deforolimus) is an inhibitor of mammalian target of rapamycin (mTOR), an important regulator in the cell survival pathway. This open-label, single center phase I study aimed ...

    Authors: Lian Liu, Wen Zhang, Wenhua Li, Fangfang Lv, Zuguang Xia, Sheng Zhang, Wen Liu, Anthe S Zandvliet, Sylvia Waajen, Li Xin Zhang, Li Yan and Jin Li
    Citation: Journal of Hematology & Oncology 2013 6:48
    Content type: Rapid communication Published on:

  24. Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. The unique structure of CAR endows T...

    Authors: Ethan Q Han, Xiu-ling Li, Chun-rong Wang, Tian-fang Li and Shuang-yin Han
    Citation: Journal of Hematology & Oncology 2013 6:47
    Content type: Review Published on:

  25. Patients with diffuse large B cell lymphoma (DLBCL) who are not candidates for or recur after autologous stem cell transplant have a poor overall prognosis. We conducted a phase II study of sorafenib (formerly...

    Authors: Daniel R Greenwald, Hailun Li, Selina M Luger, Ronald S Go, David King, Taral Patel, Randy D Gascoyne, Jill Kolesar, Brad S Kahl and Sandra Horning
    Citation: Journal of Hematology & Oncology 2013 6:46
    Content type: Research Published on:

  26. Less than 20% of patients with follicular lymphoma (FL) present with Ann Arbor Stage I or II disease at diagnosis. Numerous therapeutic options exist, however radiation therapy is considered the standard of ca...

    Authors: Anne-Sophie AS Michallet, Laure L Lebras, Deborah D Bauwens, Fadhela F Bouafia-Sauvy, Françoise F Berger, Christelle C Tychyj-Pinel, Anne A D’Hombres, Gilles G Salles and Bertrand B Coiffier
    Citation: Journal of Hematology & Oncology 2013 6:45
    Content type: Research Published on:

  27. To explore the efficacy and safety of L-asparaginase in newly-diagnosed extranodal nature killer (NK)/T –cell lymphoma (ENKTL), we conducted a prospective phase II study of L-asparaginase, cyclophosphamide, vi...

    Authors: Ningjing Lin, Yuqin Song, Wen Zheng, Meifeng Tu, Yan Xie, Xiaopei Wang, Lingyan Ping, Zhitao Ying, Chen Zhang, Lijuan Deng, Weiping Liu and Jun Zhu
    Citation: Journal of Hematology & Oncology 2013 6:44
    Content type: Rapid communication Published on:

  28. Previous reports have demonstrated that L1cam is aberrantly expressed in various tumors. The potential role of L1cam in the progression and metastasis of gastric cancer is still not clear and needs exploring.

    Authors: Dong-liang Chen, Zhao-lei Zeng, Jing Yang, Chao Ren, De-shen Wang, Wen-jing Wu and Rui-hua Xu
    Citation: Journal of Hematology & Oncology 2013 6:43
    Content type: Research Published on:

  29. With the recent addition of anti-angiogenic agents to cancer treatment, the angiogenesis regulators in platelets are gaining importance. Platelet factor 4 (PF-4/CXCL4) and Connective tissue activating peptide ...

    Authors: Katerina Pilatova, Kristina Greplova, Regina Demlova, Beatrix Bencsikova, Giannoula Lakka Klement and Lenka Zdrazilova-Dubska
    Citation: Journal of Hematology & Oncology 2013 6:42
    Content type: Review Published on:

  30. There is an unmet need for treatment options in Chinese patients with relapsed or refractory multiple myeloma (RRMM). Lenalidomide plus low-dose dexamethasone is effective and generally well tolerated in Cauca...

    Authors: Jian Hou, Xin Du, Jie Jin, Zhen Cai, Fangping Chen, Dao-bin Zhou, Li Yu, Xiaoyan Ke, Xiao Li, Depei Wu, Fanyi Meng, Huisheng Ai, Jingshan Zhang, Honeylet Wortman-Vayn, Nianhang Chen, Jay Mei…
    Citation: Journal of Hematology & Oncology 2013 6:41
    Content type: Research Published on:

  31. New genetic markers for adult acute lymphoblastic leukemia (ALL) have been found to have prognostic impact, such as the lymphoid transcription factor gene IKZF1 alterations, which are associated with a high ra...

    Authors: Yanmin Zhao, He Huang and Guoqing Wei
    Citation: Journal of Hematology & Oncology 2013 6:40
    Content type: Review Published on:

  32. Treatment of acute myeloid leukemia remains a therapeutic challenge. Even in younger patients with a low rate of co-morbidities less than 50% of patients can be cured. For older patients or patients with signi...

    Authors: Denise Wolleschak, Enrico Schalk, Christian Krogel, Tina M Schnoeder, Helga Luehr, Kathleen Jentsch-Ullrich, Thomas Fischer and Florian H Heidel
    Citation: Journal of Hematology & Oncology 2013 6:39
    Content type: Case report Published on:

  33. Breast cancer is the second most common cause of death for women behind lung cancer and the most common cause of cancer deaths for women aged 45–55 years old (CDC.gov 2012). Although there continue to be enorm...

    Authors: Jason A Incorvati, Shilpan Shah, Ying Mu and Janice Lu
    Citation: Journal of Hematology & Oncology 2013 6:38
    Content type: Review Published on:

  34. Emerging evidence showed that long non-coding RNAs (lncRNAs) play important roles in a wide range of biological processes and dysregulated lncRNAs are involved in many complex human diseases, including cancer....

    Authors: Hua Zhang, Zhenhua Chen, Xinxin Wang, Zunnan Huang, Zhiwei He and Yueqin Chen
    Citation: Journal of Hematology & Oncology 2013 6:37
    Content type: Review Published on:

  35. Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The trea...

    Authors: Mei Wu, Akintunde Akinleye and Xiongpeng Zhu
    Citation: Journal of Hematology & Oncology 2013 6:36
    Content type: Review Published on:

  36. The tumor microenvironment is a crucial determinant in tumor progression. Interstitial extracellular matrix (ECM), such as type I collagen (Col-1), is aberrantly enriched in the tumor microenvironment and prom...

    Authors: Yan Zhuang, Xiang Wang, Hong T Nguyen, Ying Zhuo, Xinpeng Cui, Claire Fewell, Erik K Flemington and Bin Shan
    Citation: Journal of Hematology & Oncology 2013 6:35
    Content type: Short report Published on:

  37. The aberrant activation of Ras signaling is associated with human diseases including hematological malignancies and vascular disorders. So far the pathological roles of activated Ras signaling in hematopoiesis...

    Authors: Chun-Guang Ren, Lei Wang, Xiao-E Jia, Yi-Jie Liu, Zhi-Wei Dong, Yi Jin, Yi Chen, Min Deng, Yong Zhou, Yi Zhou, Rui-Bao Ren, Wei-Jun Pan and Ting-Xi Liu
    Citation: Journal of Hematology & Oncology 2013 6:34
    Content type: Research Published on:

  38. Adoptive transfer of chimeric antigen receptor (CAR)-modified T cells appears to be a promising immunotherapeutic strategy. CAR combines the specificity of antibody and cytotoxicity of cytotoxic T lymphocytes,...

    Authors: Chan-Juan Shen, Yu-Xiu Yang, Ethan Q Han, Na Cao, Yun-Fei Wang, Yi Wang, Ying-Ying Zhao, Li-Ming Zhao, Jian Cui, Puja Gupta, Albert J Wong and Shuang-Yin Han
    Citation: Journal of Hematology & Oncology 2013 6:33
    Content type: Research Published on:

  39. The Austrian Azacitidine Registry is a multi-center database (ClinicalTrials.gov: NCT01595295). The nature and intent of the registry was to gain a comprehen...

    Authors: Lisa Pleyer, Reinhard Stauder, Sonja Burgstaller, Martin Schreder, Christoph Tinchon, Michael Pfeilstocker, Susanne Steinkirchner, Thomas Melchardt, Martina Mitrovic, Michael Girschikofsky, Alois Lang, Peter Krippl, Thamer Sliwa, Alexander Egle, Werner Linkesch, Daniela Voskova…
    Citation: Journal of Hematology & Oncology 2013 6:32
    Content type: Short report Published on:

  40. Anti-VEGF therapy reduces tumor blood vessels, however, some vessels always remain. These VEGF insensitive vessels may help support continued tumor growth and metastases. Many in vitro assays examining multiple s...

    Authors: Beverly L Falcon, Belinda O’Clair, Don McClure, Glenn F Evans, Julie Stewart, Michelle L Swearingen, Yuefeng Chen, Kevin Allard, Linda N Lee, Kuldeep Neote, Dyke P McEwen, Mark T Uhlik and Sudhakar Chintharlapalli
    Citation: Journal of Hematology & Oncology 2013 6:31
    Content type: Research Published on:

  41. The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers. An important V600E mutation h...

    Authors: Tiangui Huang, Michael Karsy, Jian Zhuge, Minghao Zhong and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:30
    Content type: Review Published on:

  42. Treatment options in older acute myeloid leukaemia (AML) patients include intensive chemotherapy, best supportive care (BSC), and hypomethylating agents. Currently, limited data is available on hypomethylating...

    Authors: Lieke H van der Helm, Ellen RM Scheepers, Nic JGM Veeger, Simon MGJ Daenen, André B Mulder, Eva van den Berg, Edo Vellenga and Gerwin Huls
    Citation: Journal of Hematology & Oncology 2013 6:29
    Content type: Short report Published on:

  43. The definition of immune Thrombocytopenia (ITP) as a peripheral blood platelet count less than 100 × 109/L instead of the historical criteria of 150 × 109/L renders subjects with platelets between 100 and 150 × 1...

    Authors: Andreia Maria Camargos Rocha, Cláudia Souza, Gifone Aguiar Rocha, Fabrício Freire de Melo, Nelma Cristina Diogo Clementino, Marília Campos Abreu Marino and Dulciene Maria Magalhães Queiroz
    Citation: Journal of Hematology & Oncology 2013 6:28
    Content type: Letter to the Editor Published on:

  44. Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametin...

    Authors: Akintunde Akinleye, Muhammad Furqan, Nikhil Mukhi, Pavan Ravella and Delong Liu
    Citation: Journal of Hematology & Oncology 2013 6:27
    Content type: Review Published on:

  45. The predominant mechanism by which human tumors maintain telomere length is via telomerase. In ~10% of tumor samples, however, telomere length is conserved, despite no detectable telomerase activity, in part t...

    Authors: Oumar Samassekou, Abba Malina, Josée Hébert and Ju Yan
    Citation: Journal of Hematology & Oncology 2013 6:26
    Content type: Short report Published on:

  46. Transcription factor PU.1, a member of the ETS family, is a master regulator of myeloid differentiation whose functional disruption is often associated with acute myeloid leukemia (AML). Although much has been...

    Authors: Maoxiang Qian, Wen Jin, Xuehua Zhu, Xiaohong Jia, Xianwen Yang, Yanzhi Du, Kankan Wang and Ji Zhang
    Citation: Journal of Hematology & Oncology 2013 6:25
    Content type: Research Published on:

  47. Inosine triphosphate pyrophosphohydrolase (ITPase) is a ‘house-cleaning’ enzyme that degrades non-canonical (‘rogue’) nucleotides. Complete deficiency is fatal in knockout mice, but a mutant polymorphism resul...

    Authors: Mazin A Zamzami, John A Duley, Gareth R Price, Deon J Venter, John W Yarham, Robert W Taylor, Laurence P Catley, Timothy HJ Florin, Anthony M Marinaki and Francis Bowling
    Citation: Journal of Hematology & Oncology 2013 6:24
    Content type: Research Published on:

  49. p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A breakthrough in cancer research came from the discovery of the drugs which are capable of reactivating p53 function. Most an...

    Authors: Manujendra N Saha, Lugui Qiu and Hong Chang
    Citation: Journal of Hematology & Oncology 2013 6:23
    Content type: Review Published on:

  50. Lynch syndrome (LS), an autosomal dominant inherited cancer susceptibility syndrome, also known as hereditary non-polyposis colon cancer (HNPCC), is caused by a germline mutation in one of several DNA mismatch...

    Authors: Yiying Wang, Yue Wang, Jie Li, Janiel Cragun, Kenneth Hatch, Setsuko K Chambers and Wenxin Zheng
    Citation: Journal of Hematology & Oncology 2013 6:22
    Content type: Commentary Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us